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Message from the Chairmen
These proceedings provide a flavour of the 9th International Conference on Chemical
Modifiers of Cancer Treatment. This meeting consisted of 196 oral contributions, including
keynote talks, as well as 4 minute/4 slide presentations. This format has been a feature of the
more recent Chemical Modifier meetings and the talks were accompanied by extended
abstracts given to participants at the time of the meeting.
Presentations were representative of virtually all areas covered in previous Chemical Modifier
meetings and indicated that the field is continuing to evolve. This is coming about, in part, by
the application of new techniques derived from molecular biology. Thus, redox changes that
occur in tumours (which previously have been considered major problems) are now recognised
to cause substantial changes in cellular biochemistry. This better understanding of cell and
tumour biology will provide new avenues for therapeutic exploitation.
The return of the Chemical Modifiers meeting to the UK coincides with the 'retirement' of
three pioneers in the field, namely Professors Ged Adams, Norman Bleehen and Stanley
Dische. It was they who organised the first Chemical Modifiers meeting in 1977, the
proceedings of which were published in the British Journal of Cancer (38, suppl. III). Since
then, these 'pioneers' have worked tirelessly in developing many of the concepts derived from,
and included in, later meetings. Their work has set the highest standard and it is hoped that
these proceedings provide a small tribute to these leaders, whose work one equates with
scientific excellence.
Finally, the conference and the publication of these proceedings has been made possible by the
tireless efforts of the secretarial team - Vikki Fielden and Jane McCourt at the MRC Harwell
and Simone Larche at Stockton Press. Special thanks go to the Medical Research Council and,
for generous major sponsorship, to the Cancer Research Campaign and the pharmaceutical
company Sanofi Winthrop.
Science and the field of Chemical Modifers moves on. The next meeting is in Florida, USA, in
January 1998, chaired by Professor Dietmar Siemann. Enjoy these Proceedings and look
forward to the next.
Ian Stratford, Paul Workman and Norman Coleman
(Co-Chairmen)
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